Teijin Pharma Limited, the core company of the Teijin Group’s medical and pharmaceutical business, has launched Mucosolvan L tablet 45 mg (ambroxol hydrochloride), a reduced-size tablet version of the company's novel expectorant drug.
This sustained-release tablet measures just 7.5 mm x 6 mm, making it smaller and easier to swallow than conventional once-daily expectorant drugs. It contains the same active ingredient as Mucosolvan L capsule 45mg, a once-daily product now on the market. It is also expected to have the same effect, especially when administered after dinner for the treatment of productive sputum the following morning.
The medical field has high expectations for the tablet’s reduced size, as expectorants are often taken with other drugs.
Expectorant drugs for respiratory diseases, such as bronchitis and chronic obstructive pulmonary disease (COPD), reduce sputum adhesion to the trachea and the bronchus. More than 60 per cent of patients with chronic respiratory diseases such as COPD suffer productive sputum in the morning.
Mucosolvan, licensed by Boehringer Ingelheim opening a new window and sold since 1984, meets the needs of those who prefer a formulation other than a liquid, syrup or once-daily capsule.
Teijin is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare.